116062-22-7

Basic information

• Product Name: 6-chloro-N4-(4-methoxybenzyl)pyrimidine-4,5-diamine
• Synonyms: 6-chloro-N4-(4-methoxybenzyl)pyrimidine-4,5-diamine
• CAS NO: 116062-22-7
• Molecular Formula: C₁₂H₁₃ClN₄O
• Molecular Weight: 264.71082
• Mol File: 116062-22-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6-chloro-N4-(4-methoxybenzyl)pyrimidine-4,5-diamine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-chloro-N4-(4-methoxybenzyl)pyrimidine-4,5-diamine(116062-22-7)
• EPA Substance Registry System: 6-chloro-N4-(4-methoxybenzyl)pyrimidine-4,5-diamine(116062-22-7)

Safety Data

• Hazardous Substances Data: 116062-22-7(Hazardous Substances Data)

Usage

Chemical compound

6-chloro-N4-(4-methoxybenzyl)pyrimidine-4,5-diamine

Primary use

Research purposes in the pharmaceutical industry

Derivative of

Pyrimidine

Contains

Chlorine atom and a 4-methoxybenzyl group

Biological activities

Potential antiproliferative agent in cancer treatment, potential antimicrobial and antiviral properties

Research applications

Development of new drugs, medicinal chemistry

Potential therapeutic properties

Promise in various research applications

Upstream product

• 5413-85-4 5-amino-4,6-dichloropyridimine 
• 2393-23-9 4-methoxy-benzylamine 
• 651013-61-5 6-chloro-N-(4-methoxybenzyl)-5-nitropyrimidin-4-amine 
• 71-36-3 butan-1-ol 

Downstream Products

• 1173900-32-7 6-(2-furyl)-N⁽⁴⁾-(4-methoxybenzyl)pyrimidine-4,5-diamine 
• 869854-18-2 7-chloro-[3-(4-methoxybenzylamino)]-3H-[1,2,3]triazolo[4,5-d]pyrimidine 
• 174698-22-7 4-[[(6-phenethylamino-5-valeramido) pyrimidin-4-yl]aminomethyl]anisole 
• 174698-21-6 4-[[(6-benzylamino-5-valeramido) pyrimidin-4-yl]aminomethyl]anisole 

Relevant articles and documents

HETEROCYCLIC AMIDE COMPOUND

Provided is a heterocyclic amide compound that may have a PRS inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for PRS associated diseases and the like including cancer. A compound represented by the following formula

CYCLIC DI-NUCLEOTIDE COMPOUNDS AND METHODS OF USE

Disclosed are cyclic-di-nucleotide cGAMP analogs, methods of synthesizing the compounds, pharmaceutical compositions comprising the compounds thereof, and use of compounds and compositions in medical therapy.

Synthesis and biological evaluation of pyrimidine analogs of antimycobacterial purines

Pyrimidine analogs of antimycobacterial 6-aryl-9-benzylpurines have been synthesized and screened for antibacterial activity against Mycobacterium tuberculosis H37Rv in vitro. Several active compounds were identified and the best results were o

Synthesis of non-purine analogs of 6-aryl-9-benzylpurines, and their antimycobacterial activities. Compounds modified in the imidazole ring

Purine analogs modified in the five-membered ring have been synthesized and examined for antibacterial activity against Mycobacterium tuberculosis H 37Rv in vitro employing the microplate alamar blue assay (MABA). The 9-deaza analogs were only

Synthesis and antimycobacterial activity of 5-formylaminopyrimidines; analogs of antibacterial purines

Pyrimidine analogs of antimycobacterial purines have been synthesized and their biological activities evaluated. Several 5-formamidopyrimidines exhibited profound activity against Mycobacterium tuberculosis in vitro (IC90 ≤ 1.5 μg/mL), and they

Compounds containing a N-heteroaryl moiety linked to fused ring moieties for the inhibition of NAD(P)H oxidases and platelet activation

The invention relates to compounds containing a N-heteroaryl moiety, which is linked via oxygen, sulfur or nitrogen, or via a methylene bridge and oxygen, sulfur or nitrogen to a fused ring moiety, in particular to the 1,2,3-triazolo[4,5-d]pyrimidine-7-yl radical. The invention also relates to a process for the preparation of said compounds and the use thereof in drugs for the treatment of NAD(P)H oxidases-related diseases and disorders and inhibition of platelet activation.

Novel imidazopyrimidinyl and imidazopyri dinyl derivatives

Provided herein are compounds of the formula (I): 1 as well as stereoisomers and pharmaceutically acceptable salts thereof. Such compounds are, because of their ability to antagonize CRF, useful in the treatment of a variety of disorders characterized by

Pyrimidine derivatives and pharmaceutical composition

A pyrimidine derivative of the formula (I): STR1 wherein R1 is a hydrogen atom, alkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, or --NHR11 group; R2 is a hydrogen or halogen atom, alkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, --(CH2)m C6 H5, --NH2, --NHR12, --NH(CH2)n C6 H5, --NH(CH2)p C6 H4 --OR13, --N(R14)(CH2)q C6 H5, --NHC(=O)R15, --NHC(=O)(CH2)r C6 H5, --NHC(=O)CH(C6 H5)2, --OR16, or --O(CH2)s C6 H5 group; R3 is --COOH, --COOR17, hydroxyl, --OR18, --NH2, --N(R19)2, --NHR20, azole, or sulfonic acid group; R11 is alkyl of 1 to 6 carbon atoms or haloalkyl of 1 to 6 carbon atoms; R12, R13, R14, R15, R16, R17, R18, R19, and R20 are independently alkyl of 1 to 6 carbon atoms; m is 0 or an integer of 1 to 6; n is 0 or an integer of 1 to 6; p is 0 or an integer of 1 to 6; q is 0 or an integer of 1 to 6; r is 0 or an integer of 1 to 6; and s is 0 or an integer of 1 to 6, or a salt thereof, and a pharmaceutical composition comprising said pyrimidine derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier are disclosed.

(4-piperidinylmethyl and -hetero) purines

(4-Piperidinylmethyl and -hetero)purines having antihistaminic properties and being useful agents in the treatment of allergic diseases.